N/A
N=160
Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Bottom Line
View on ClinicalTrials.gov: NCT01027468 ↗Enrolled (actual)
160
Serious AEs
3.1%
Results posted
Feb 2014
Primary outcome: Primary: Vision — 0.16 logMAR
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bevacizumab (Drug)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Medical University of Vienna
- Primary completion
- Nov 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Vision |
0.16 | — |
| PRIMARY CRT (Central Retinal Thickness) |
319 | — |
| SECONDARY Systemic Complications After Treatment |
0; 0; 5; 0 | — |
Summary
200 eyes with each subtype of neovascular age-related macular degeneration will be included in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual acuity (BCVA) will be measured using Snellen charts at 6m. Central retinal thickness (CRT) will be measured using Stratus OCT and Cirrus SD-OCT (Zeiss). Data of treatment-naive eyes (group 1) were compared to the data of eyes that had undergone prior treatment with photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide (group 2).
Eligibility Criteria
Inclusion Criteria
- any subtype of neovascular age-related macular degeneration
- age of 50 years or older
- initial treatment with intravitreal bevacizumab between August 2005 and June 2006
Exclusion Criteria
- previous vitrectomy
- presence of cystoid macular edema without choroidal neovascularization
- Uncontrolled systemic disease
Data sourced from ClinicalTrials.gov (NCT01027468). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.